Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | ACP3 | P15309 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CTSG | P08311 | 1/20 | 0.32 |
| ▸ | CMA1 | P23946 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2326062 | 0.83 | AOC3 (0.39) | AOC3CYP2C9CYP2C19HPGDHTT | |
| SCHEMBL2326069 | 0.83 | AOC3 (0.39) | AOC3CYP2C9CYP2C19HPGDHTT | |
| SCHEMBL8038236 | 0.81 | AOC3 (0.40) | AOC3CYP2C9CYP2C19HPGDHTT | |
| SCHEMBL8028264 | 0.79 | KDM4E (0.42) | AOC3CYP2C9KDM4E | |
| SCHEMBL24313989 | 0.78 | THRB (0.39) | CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL2026529 | 0.76 | ALDH1A1 (0.41) | CYP2C9CYP2C19HPGDHTTALDH1A1 | |
| SCHEMBL28961046 | 0.75 | CYP2C9 (0.40) | CYP2C9CYP2C19HPGDHTTALDH1A1 | |
| SCHEMBL3173706 | 0.75 | LMNA (0.40) | CYP2C9CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL5270052 | 0.72 | TSHR (0.46) | CYP2C9CYP2C19HPGDHTTALDH1A1 | |
| SCHEMBL9572786 | 0.72 | CYP1A2 (0.42) | AOC3CYP2C9CYP2C19ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149440-B2 | Nanoparticles for drug-delivery | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-10-06 | — | — | US | disclosed |
| US-20070190160-A1 | Nanoparticles for drug-delivery | UNIVERSITY OF SOUTH FLORIDA | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070190160-A1 | Nanoparticles for drug-delivery | EPCAM, TUBB1, ACTB | AOC3 2377/4885CYP2C9 3584/4885CYP2C19 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.